Stereotaxis, Inc. STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026
Stereotaxis, Inc. (STXS) is a healthcare company listed in the US with a market value of about $84M. In the twelve months to June 30, 2026 it had revenue of $30M and net income of -$22M, a net margin of -74.2%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -81%.
About Stereotaxis
Stereotaxis is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus. Revenue went from $35M in 2014 to $32M in 2025, a decline of about 0.7% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders). It spends 29% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30M | $32M | $27M | $27M | $28M | $35M | $27M | $29M | $29M | $31M | $32M |
| Net income | -$22M | -$22M | -$24M | -$21M | -$18M | -$11M | -$7M | -$5M | $116756 | -$6M | -$5M |
| Free cash flow | -$16M | -$14M | -$9M | -$10M | -$11M | -$4M | -$4M | -$5M | -$3M | -$5M | -$7M |
| EPS (diluted) | $-0.24 | $-0.25 | $-0.30 | $-0.27 | $-0.26 | $-0.16 | $-0.11 | $-0.10 | $-0.03 | $-0.32 | $-0.54 |
| Net margin | -74.2% | -66.8% | -89.3% | -77.4% | -65.0% | -30.6% | -25.0% | -15.9% | 0.4% | -18.9% | -16.4% |
| ROIC | — | -92.3% | -161.7% | -79.0% | -46.1% | -25.5% | -13.6% | -14.1% | -148.0% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Stereotaxis pay a dividend?
Not currently.
Is Stereotaxis a good stock to buy?
We do not give buy or sell advice. Stereotaxis scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.